Your browser doesn't support javascript.
Characterization of a broadly cross reactive tetravalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS-CoV-2.
Garg, Sonal; Raj, Nisha; Lukose, Asha; Jamwal, Deepti; Parray, Hilal Ahmed; Kumar, Sandeep; Dhyani, Samridhi; Jakhar, Kamini; Sonar, Sudipta; Tiwari, Mahima; Mani, Shailendra; Bhattacharyya, Sankar; Sharma, Chandresh; Shrivastava, Tripti; Kumar, Rajesh.
  • Garg S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Raj N; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Lukose A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Jamwal D; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Parray HA; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Kumar S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Dhyani S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Jakhar K; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Sonar S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Tiwari M; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Reema; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Mani S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Bhattacharyya S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Sharma C; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
  • Shrivastava T; Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India.
  • Kumar R; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana 121001 India.
3 Biotech ; 12(9): 202, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1971859
ABSTRACT
We used human semi-synthetic phage antibody gene libraries to select anti-SARS-CoV-2 RBD scFv antibody fragment and subsequent characterization of this novel tetravalent monoclonal antibody targeting conformational epitopes in the receptor binding domain of SARS-CoV-2. Binding studies suggest that II62 tetravalent antibody cross-reacts with RBD protein of SARS-CoV2 and its different variants of concerns. The epitope mapping data reveals that II62 tetravalent antibody targets an epitope that does not directly interferes with RBD ACE2 interaction. Neutralization studies with live authentic SARS-CoV2 virus suggests that increase in valency of II62 mAb from monovalent to tetravalent doesn't perturbate virus interactions with the ACE2 expressing host cells in cytopathic effect-based (CPE) assay. Supplementary Information The online version contains supplementary material available at 10.1007/s13205-022-03272-6.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Randomized controlled trials Topics: Variants Language: English Journal: 3 Biotech Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Randomized controlled trials Topics: Variants Language: English Journal: 3 Biotech Year: 2022 Document Type: Article